Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Small Molecule Formulation Development: Strategies for challenging APIs (jointly with AAPS-BADG)


Speakers: Tom Chiang (Genentech), Vahid Zia (Gilead), Andrew Phimister (Seaview Pharma Solutions), et al.
Organizers: Vibha Puri (Genentech), Edward Yost (Genentech), Lu Lu (WuXi AppTec), Rajiv Nayar (HTD Biosystems Inc.), Shichang Miao (ChemoCentryx)
Date: 2018-09-27
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Catalent Pharma Solutions; Quotient Sciences
Vendor show vendors registered to date: (9)Absorption Systems; BioDuro; Celerion; Concept Life Sciences; CoreRx, Inc.; Foster Delivery Science, Inc; Nitto Avecia Pharma Services; Pion Inc.; Zef Scientific
Registration: http://www.PBSS.org
Registration deadline:2018-09-26  (it will close sooner if the seating cap is reached)

About the Topic

The pharmaceutical industry is focusing on more challenging biological targets to address unmet medical needs. These new targets are increasingly more difficult to drug due to their lipophilicity and complex mode of actions. Medicinal chemists are therefore creating new molecular entities that often have low solubility, permeability, or both low solubility and permeability. This requires scientists to challenge the current formulation development paradigm.  Identifying innovative strategies for drug development helps to shift the industry from empirical to more mechanistic approaches. The benefit is the ability to have flexible formulation strategies that can adjust to meet pre-clinical and clinical demands, while also meeting the requirements of a dynamic regulatory environment. This workshop will survey current formulation practices and how they are changing to address challenging APIs.  The evolving science includes knowing new technologies and how to take advantage of them.  Furthermore, discussions will focus on the mechanistic understanding of formulations which help to ensure successful drug products that meet quality-by-design (QbD) regulatory requirements.

This workshop will cover the following topics:

  • Overview of formulation development — pre-clinical to market image formulation
  • Essential DMPK concepts for the formulation scientists
  • New analytical tools and strategies for formulation development
  • Material sparing approaches to reduce cost and time while increasing formulation understanding
  • Particle engineering to address poor API PK properties
  • Regulatory and clinical requirements for a successful drug product

Workhop Agenda

8:00 – 8:45 am   Registration

8:45 – 9:00 am   Introduction

9:00 – 9:50 am   “Practical Application of Biopharmaceutical Tools to Guide Formulation Strategy” - Andrew Phimister – Seaview Pharma Solutions

9:50 – 10:40 am   “An integrated approach to evaluate the solubility target for salts for the oral drug delivery” - Tom Chiang - Genentech

10:40 – 11:00 am   Break

11:00 – 11:10 am   Sponsor presentation

11:10 – 12:00 pm   “Enhancing Biopharmaceutical Properties of Poorly Soluble Compounds: Formulation and Process Development” - Vahid Zia – Gilead

12:00 – 1:20 pm   Lunch

1:20 – 2:10 pm   “Formulation Strategies for High Dose Toxicology Studies” Dennis Leung – Genentech

2:10 – 3:00 pm   “Formulating Challenging API with Liposomal technologies:  Challenges, Limitations, and Opportunities” - Rajiv Nayar – HTD Biosystems

3:00 – 3:15 pm   Break

3:15 – 3:25 am   Sponsor presentation

3:25 – 4:15 pm   “Late-Stage Formulation Development Challenges” - Ravi Mahalingam – ReechPharma

4:15 – 4:45 pm   Panel Discussion

4:45 – 5:00 pm   Closing Remarks


2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/15/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad